US2016074492A1PendingUtilityA1
Oral Vaccine For Borrelia
Est. expiryJul 2, 2024(expired)· nominal 20-yr term from priority
A23K 1/009A61K 2039/523A61K 9/0053A23L 1/3014C07K 14/20A61K 39/0225A23K 10/18Y02A50/30A61K 2039/552A61K 2039/541A23V 2002/00A23L 33/135A61K 2039/54A23V 2400/169
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.
Claims
exact text as granted — not AI-modified1 . A composition comprising a bacterium engineered to express at least one outer surface protein of Borrelia burgdorferi.
2 . The composition of claim 1 , wherein said bacterium comprises lyophilized E. coli.
3 . The composition of claim 1 , wherein said bacterium comprises a lactobacillus selected from the group consisting of L. acidophilus, L. brevis, L. casei, L. crispatus, L. fermentum, L. gasseri, L. plantarum, L. reuteri, L. rhamnosus , and L. salivarius.
4 . The composition of claim 1 , wherein said lactobacillus comprises L. plantarum.
5 . The composition of claim 1 , wherein said at least one outer surface protein comprises an OspA fragment of at least 100 amino acids that is at least 90% identical to the amino acid sequence set forth as SEQ ID NO:2.
6 . The composition of claim 1 , wherein said at least one outer surface protein comprises an OspA fragment of at least 200 amino acids that is at least 80% identical to the amino acid sequence set forth as SEQ ID NO:2.
7 . The composition of claim 1 , wherein said at least one outer surface protein comprises an OspA fragment with a mutated hLFA1 epitope.
8 - 12 . (canceled)
13 . An oral vaccine composition comprising at least one bacterium engineered to express at least one Borrelia burgdorferi outer surface protein, and a food carrier or an excipient.
14 . The composition of claim 13 , wherein said bacterium is selected from the group consisting of Escherichia coli , and Lactobacillus plantarum.
15 . The composition of claim 13 , wherein said bacterium is lyophilized.
16 . The composition of claim 13 , wherein said food carrier comprises a dairy product selected from the group consisting of milk, yogurt, and cheese, or a grain product selected from the group consisting of grain, seed, bread, and cereal.
17 . The composition of claim 13 , wherein said excipient is selected from the group consisting of a sugar, a starch, a gum, and a protein.
18 . The composition of claim 13 , wherein said food carrier comprises animal chow.
19 . (canceled)
20 . A kit comprising the oral vaccine composition of claim 13 , and instructions for orally administering said oral vaccine composition.
21 - 30 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.